Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study
Clinical trial NCT07516132 · RECRUITING
Trial details
- NCT number
- NCT07516132
- Sponsor
- Ocular Therapeutix, Inc.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-04-27
- Primary completion
- 2030-08-01
- Enrollment
- 850
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.